It has been estimated that about one-third of children with so-called idiopathic hypoglycaemia are leucine sensitive (Mabry, Di George, and Auerbach, 1960) . However, the total number of leucine-sensitive cases reported is still relatively small. In 1960, Di George and Auerbach knew of no more than 30 cases and only a few have been reported since then. We therefore describe two further cases, one of which has been followed up for five years. All authors are agreed that until recently treatment has been difficult. However, the advent of diazoxide, a hyperglycaemic benzothiadiazine derivative, may in future make treatinent easier. Our two patients were given this drug and we report the clinical results together with observations of its effect upon blood insulin levels.
Clinical Details and Preliminary Investigation Case 1. He is the second child in a family of three, the other children being normal. He was born at term following an easy forceps delivery and the neonatal period was normal. At the age of 2 months he developed convulsions. Initially these took the form of typical infantile spasms of the flexor type; later minor fits occurred consisting of episodes in which he became quiet and limp. Although he first smiled at 4 weeks, subsequent progress was slow and at the age of 5 months, when first seen at the Birmingham Children's Hospital, head control and visual fixation were poor. A convulsion occurred during his first out-patient attendance during which a blood sugar estimation was 54 mg./ 100 ml. He was admitted to hospital. Further investigations at that time showed: developmental quotient (DQ), 35; EEG, grossly and diffusely abnormal and epileptic hypsarrhythmia; blood calcium 9.9 mg./100 ml., and skull x-ray examination normal.
The significance of the slightly low blood sugar was not appreciated at the time. It cause for these hypoglycaemic episodes, and the diagnosis was confirmed by an oral leucine sensitivity test (Table) . This showed a pronounced fall in the blood sugar to 25 mg./100 ml. at 45 minutes, when a convulsion occurred. Treatment consisted of reducing the leucine content of his diet together with added glucose supplements. He had previously been fed with a proprietary dried cows' milk (Ostermilk No. 2) . The leucine content of another proprietary preparation (S.M.A. Wyeth) is only 40% of cow's milk and he was accordingly fed with this preparation, but large quantities of added glucose (120 g./day) were required before the hypoglycaemic episodes were satisfactorily controlled. His protein intake at this stage was only 12 g./day. (Morgan and Lazarow, 1963 The most prominent side-effect observed has been hirsutism. Case 1 displayed increasing hirsutism after the first two months of therapy, a thick growth of hair blood sugar levels before developing over the forehead, eyebrows, extremities, and {e therapy.
in particular over the lumbo-dorsal spine (Fig. 6) Discussion The nature of the metabolic defect in leucine sensitivity is still incompletely understood. An important step in the understanding of the cause of the hypoglycaemia was the finding of increased serum insulin levels in leucine-sensitive patients following the oral administration of leucine (Payne and Woolf, 1959; Yalow and Berson, 1960) . From the experiments of Butterfield, Whichelow, Wright, and Woolf (1960) , it seems clear that leucine has no direct effect on the glucose uptake of peripheral tissues in patients sensitive to this amino acid. It has been shown that sulphonylureas produce a decrease in the plasma sugar level by direct stimulation of beta-cell insulin production. Pre-treatment with chlorpropamide has induced leucine-sensitive hypoglycaemia in normal subjects as a result of excessive insulin secretion (Fajans, Knopf, Floyd, Power, and Conn, 1963) . It seems likely, therefore, that the excessive insulin secretion in leucinesensitive hypoglycaemia results from the stimulation of the pancreatic beta-cells. Histological reports in these cases have been few, but the finding of betacell degranulation (Cochrane, Payne, Simpkiss, and Woolf, 1956) or hyperplasia (Rosenthal, Metz, and Pirani, 1964) suggests a state of prolonged secretory stimulation.
The majority of cases of leucine-sensitive hypoglycaemia recorded to date have shown moderately severe mental retardation, and microcephaly is a common feature. The only recorded case with normal development is a child described by Griese and Wenzel in 1965 , who was developmentally normal at 2 years of age. Gentz, Lehmann, and, Zetterstrom (1962) suggest that brain atrophy may be more common in leucine-sensitive hypoglycaemia than in other varieties. The hypoglycaemia is likely to be most profound in the neonatal period or early infancy at a time when the developing brain is most susceptible to hypoglycaemic damage. Prevention of cerebral damage, therefore, demands prompt recognition of the condition and effective control of further hypoglycaemia. Earlier diagnosis will follow the increasing awareness of this condition which is now apparent. The modified leucine sensitivity test, as described, should prevent significant hypoglycaemia during diagnosis.
The treatment of this condition has previously been based on dietary principles. By feeding a diet low in L-leucine together with frequent carbohydrate supplements, attacks of hypoglycaemia can be reduced. Human breast milk has a leucine content of only 40% of cows' milk. A proprietary preparation, S.M.A. (Wyeth), has a leucine content similar to human breast milk and this preparation provides a suitable milk feed in infancy. Leucine is an essential amino acid. Rose, Wixom, Lockhart, and Lambert (1955) suggest that for a normal healthy adult the safe (twice minimal requirements) intake is approximately 2 2 g./day of leucine and 1 -4 g./ day of isoleucine. For growing children, however, the requirements may be several times greater. To control hypoglycaemia in many leucine-sensitive children, daily intakes considerably below optimal growth requirements may be needed, leading to suppression of growth (Rosenthal et al., 1964 Griese and Wenzel (1965) report the successful use of a long-acting epinephrine, but 8-hourly subcutaneous administration was required, the dose being regulated by the blood sugar level. Several authors advocate pancreatectomy as a means of controlling the hypoglycaemia if other measures are unsuccessful (Grumbach and Kaplan, 1960; Koop, Hamilton, Baker, and Kaye, 1966) . This is an operation with an appreciable mortality and morbidity and was unsuccessful in one of Cochrane's cases (Cochrane et al., 1956 ) and in the case described by Griese and Wenzel (1965) .
Human growth hormone (HGH) has also been used to treat hypoglycaemia of organic origin in adults (Mahon, Mitchell, Steinke, and Raben, 1962) and 'idiopathic hypoglycaemia of infancy' (Soyka, Molliver, and Crawford, 1964) . However, the use of HGH is limited by its scarcity and by other hormonal side-effects, so that prolonged treatment is not feasible.
Thiazide derivatives, the first of which, chlorothiazide, was introduced in 1957, have proved satisfactory diuretics and mild hypotensive agents. The search for a more potent hypotensive agent led to the preparation of a benzothiadiazine derivative, diazoxide (3 methyl 7 chloro 1-2-4 benzo thiadiazine 1-1 dioxide), in the laboratories of the Schering Corporation, New Jersey (Rubin, Roth, Winbury, Topliss, Sherlock, Sperber, and Black, 1961) . Disturbed carbohydrate tolerance following therapy with thiazide diuretics was described by Wilkins (1959) and Freis (1959) who found that these agents caused hyperglycaemia in some hypertensive patients. Dollery, Pentecost, and Samaan (1962) used diazoxide in combination with an ordinary thiazide diuretic to treat two hypertensive patients. In both patients diabetes mellitus developed acutely within four weeks of the start of therapy. Serum insulin studies in one of the patients after the onset of diabetes showed that the insulin-like activity was low, suggesting that the diabetes was caused by an inhibitory action on the pancreatic beta-cells. In both patients the level returned to normal within two weeks of discontinuing treatment. Samaan, Dollery, and Fraser (1963) later confirmed a lowering of serum insulin-like activity in four patients with diabetes mellitus precipitated or worsened by benzothiadiazine derivatives. The inhibition of insulin release following treatment with diazoxide and trichlormethiazide was also confirmed by Seltzer and Alen (1965) .
A drug capable of inhibiting insulin release, such as diazoxide, has obvious application in leucineinduced and other hypoglycaemic states which are associated with excess insulin production. Ernesti, Mitchell, Raben, and Gilboa (1965) reported the successful use of diazoxide to control hypoglycaemia in a 76-year-old woman with an islet cell tumour of the pancreas. Wolff, Nabwangu, Staquet, Viktora, Yabo, and Zarday (1965) report its use in treating hypoglycaemia occurring in association with adenocarcinoma, islet cell tumour, and of 'functional' origin. Drash and Wolff (1964) used diazoxide in treating a 4-year-old boy with leucine-sensitive hypoglycaemia who had previously failed to respond to ACTH corticosteroids, testosterone, human growth hormone, and partial pancreatectomy. Following therapy with diazoxide (4 mg./kg.) a steady rise in post-prandial blood sugar occurred and the patient was able to tolerate a 26-hour fast.
In our experience diazoxide has proved an advance in treatment of this condition. Before its use in Case 1 dietary management had been difficult and the child's parents had found strict dietary control difficult to achieve. No episodes of hypoglycaemia have occurred in either case during diazoxide therapy.
The occurrence of hirsutism may be alarming to both parents and physician. In Case 1 we felt that its extent justified a reduction in dosage. The effects of hypoglycaemia become less damaging with increasing age, and his progress suggests that therapy may eventually be discontinued. During infancy, however, the risks of hypoglycaemia outweigh the emotional effects of hirsutism.
A drug which is related to compounds known to cause bone-marrow depression must be prescribed with caution and though no haematological effects have been observed in this study a careful watch must obviously be maintained. The precise place of diazoxide in the treatment of this serious condition will only become clear with further experience of patients treated with it.
Summary
Two cases of leucine-sensitive hypoglycaemia are described. Both cases showed raised serum insulin levels during leucine-induced hypoglycaemia. Treatment with diazoxide, a hyperglycaemic benzothiadiazine derivative, resulted in inhibition of the hyperinsulinism and satisfactory control of the hypoglycaemia.
Diazoxide represents an advance in the treatment of this condition.
